Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Spina, M.
Right arrow Articles by Tirelli, U.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Spina, M.
Right arrow Articles by Tirelli, U.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 15:993-995, 2004
© 2004 European Society for Medical Oncology

HIV-related non-Hodgkin's lymphoma (HIV-NHL) in the era of highly active antiretroviral therapy (HAART): some still unanswered questions for clinical management

M. Spina and U. Tirelli*

Division of Medical Oncology A, National Cancer Institute, Aviano, Italy

* Email: omaoffice@cro.it

Key words: bone marrow transplantation, chemotherapy, HAART, HIV infection, non-Hodgkin's lymphoma

The first 150 words of the full text of this article appear below.

Since the beginning of the AIDS epidemic the treatment of HIV-related non-Hodgkin's lymphoma (HIV-NHL) has been a challenge. Before the introduction of highly active antiretroviral therapy (HAART) in the management of these patients, the prognosis of HIV-NHL was poor, despite a high response rate, owing to aggressive tumor behavior, increased hematological toxicity and a high rate of opportunistic infections (OIs) [1Go, 2Go]. Since the widespread use of HAART, the prognosis of HIV-NHL has improved, with a better tolerance to chemotherapy, a higher complete remission (CR) rate, a significant improvement of disease-free survival (DFS) and a significant reduction in the number of deaths related to HIV complications [3Go–5Go]. Many studies have shown that the CHOP regimen (cyclophosphamide, doxorubicin, vincristine and prednisone) can be considered the standard approach for patients with aggressive NHL in the HIV setting [6Go, 7Go], even though a recent study of the . . . [Full Text of this Article]

Continous infusion chemotherapy

Rituximab plus chemotherapy

Burkitt versus diffuse large B-cell

High-dose chemotherapy

Conclusions


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?